ASX
LCT 0.125   Last updated 12.42 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Scientific advisors

In September 2014 LCT appointed three high-level scientific advisors to review and support its work as NTCELL progresses towards commercialisation. The appointments are Professors  Roger Barker from Cambridge, Richard Faull from Auckland and Anne Young from Harvard. All are internationally recognised experts on the discovery of new treatments for neurodegenerative diseases. 


Roger BarkerProfessor Roger Barker, MD PhD FRCP, Professor of Clinical Neurosciences and Deputy Director, John van Geest Centre for Brain Repair, University of Cambridge, United Kingdom, has extensive experience in evaluating and developing new therapies for Parkinson’s and Huntington’s diseases including cell therapies. His studies focus on disease heterogeneity using cognitive testing, functional imaging and genetic biomarkers. 

 

Professor Sir Richard Faull, ONZM MBChB PhD DSc FRSNZ, Distinguished Professor of Anatomy and Director, Centre for Brain Research, University of Auckland School of Medicine, has over 40 years’ research experience in anatomical studies of human brain neuronal growth. He directs the Centre for Brain Research which carries out research and development programs targeting neurodegenerative diseases such as Parkinson’s, Huntington’s, motor neurone and Alzheimer’s diseases.

 

Professor Anne B Young, MD PhD, Distinguished Julieanne Dorn Professor of Neurology, Harvard Medical School, Boston, United States, has over 40 years’ experience studying functional neuroanatomy. Her current research focuses on studies of new therapeutic strategies for Parkinson’s and Huntington’s diseases.

Centre for Brain Research

University of Auckland - Centre for Brain Research LogoIn September 2014 LCT formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCT’s lead product NTCELL®.

 

Directed by Professor Sir Richard Faull, ONZM MBChB PhD DSc FRSNZ, University of Auckland Distinguished Professor, the CBR has a specialised interest in neurodegenerative diseases such as Parkinson’s, Huntington’s, motor neurone and Alzheimer’s diseases.

 

We expect to use our expertise to identify and commercialise treatments and products from CBR research.

Diatranz Otsuka Limited

In 2011 Living Cell Technologies established the joint venture Diatranz Otsuka Limited (DOL) in partnership with Otsuka Pharmaceutical Factory, Inc. (OPF). DOL is a private company incorporated in New Zealand.

DOL is concentrating its research and development activities in support of OPF's development of DIABECELL in the United States. Once registered in the United States, DOL retains the royalty-free right to commercialise the FDA-approved product in the rest of the world.

PRINT PAGE
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.